# US Transplantation Market

> US Transplantation Market Research Report By Product Type (Tissue Products, Immunosuppressive Drugs, Preservation Solutions), By Application (Organ Transplantation, Tissue Transplantation) and By End User (Hospitals, Transplantation Centers, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.5%
- **2024:** $ 4,131.43 Million
- **2025:** $ 4,523.92 Million
- **2035:** $ 11,213.9 Million
- **Key Players:** AbbVie (US), Thermo Fisher Scientific (US), Medtronic (US), Fresenius Medical Care (DE), Astellas Pharma (JP), Novartis (CH), Bristol-Myers Squibb (US), Sandoz (CH), Organogenesis (US)

**Report ID:** MRFR/HC/14333-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-transplantation-market-15860

---

## Market Summary

## **US Transplantation Market Overview**

As per MRFR analysis, the US Transplantation Market Size was estimated at 3.23 (USD Billion) in 2023. The US Transplantation Market Industry is expected to grow from 3.54(USD Billion) in 2024 to 10.95 (USD Billion) by 2035. The US Transplantation Market CAGR (growth rate) is expected to be around 10.811% during the forecast period (2025 - 2035).

### **Key US Transplantation Market Trends Highlighted**

The US Transplantation Market is currently experiencing significant trends driven by advancements in medical technology, increasing awareness about organ donation, and evolving medical practices. Key market drivers include the rising incidence of chronic diseases, which is increasing the demand for organ transplants. As more people suffer from conditions such as diabetes and cardiovascular diseases, the need for organ transplant procedures continues to grow. Furthermore, the number of transplant surgeries is increasing due to better surgical techniques and post-operative care, which is enhancing patient outcomes and survival rates.

In recent times, there is heightened interest in innovative approaches such as xenotransplantation and engineered organs. Researchers are exploring the possibilities of using animal organs and bioengineered tissues to address the organ shortage crisis in the United States. This development presents opportunities to be explored, especially as regulatory frameworks evolve to accommodate such advancements. The integration of artificial intelligence in donor matching processes is another promising opportunity that could lead to improved efficiency and success rates in transplantation procedures.

The ongoing campaigns promoting organ donation awareness are reshaping public perception and encouraging more individuals to consider donating their organs. The US-based organizations, such as the Health Resources and Services Administration (HRSA), play a crucial role in increasing the number of registered donors. Additionally, collaborations between hospitals and transplant centers are strengthening, which helps to streamline processes and enhance the overall transplantation network. The combination of these trends underscores a transformative period for the US Transplantation Market, with a focus on improving access and success rates for those awaiting transplants.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Transplantation Market Drivers**

### **Increasing Incidence of Organ Failure and Chronic Diseases**

The US Transplantation Market Industry is significantly driven by the rising incidence of organ failure and chronic diseases, including diabetes and cardiovascular diseases. According to data from the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans have diabetes, a condition that significantly raises the risk of developing kidney failure. The United States Renal Data System reported that around 785,883 people were living with end-stage renal disease in 2019, indicating a growing demand for kidney transplants.

Established organizations such as the American Society of Transplantation work towards educating the public on transplantation and advocating for the need for organ donation. The increase in chronic diseases leading to organ failure presents a significant opportunity for growth in the US Transplantation Market, contributing to forecasts predicting substantial market expansion in the coming decade.

### **Advancements in Surgical Techniques and Medical Technologies**

The US Transplantation Market Industry is also being propelled by advancements in surgical techniques and medical technologies, enhancing the success rates of organ transplants. Innovations such as minimally invasive surgical methods and the use of advanced imaging techniques improve patient outcomes and reduce recovery times. The American College of Surgeons has highlighted the importance of these advancements in increasing the number of successful transplants. For instance, laparoscopic donor nephrectomy has become the standard practice for kidney donation, leading to a 30% reduction in post-operative complications.

As these technologies continue to develop, they can accommodate a larger number of patients, thus supporting market growth.

### **Growing Awareness and Support for Organ Donation**

Growing public awareness and support for organ donation are vital drivers for the US Transplantation Market Industry. Campaigns led by organizations such as Donate Life America have increased participation in organ donation programs, resulting in over 39,000 organ transplants in the year 2021 alone, as reported by the Organ Procurement and Transplantation Network. According to the Health Resources and Services Administration, 104 million Americans are registered organ donors, a number that has doubled in the last decade.

Higher awareness and registration rates are essential for boosting the availability of donor organs, thereby directly impacting the growth potential of the transplantation market in the United States.

## **US Transplantation Market Segment Insights**

### **Transplantation Market Product Type Insights**

The US Transplantation Market is experiencing significant growth, driven by advancements in medical technology and increasing organ transplantation rates. Focusing on the Product Type segmentation, key components include Tissue Products, Immunosuppressive Drugs, and Preservation Solutions. Tissue Products play a critical role in transplant procedures, providing essential structural support for organ transplants and facilitating recovery for patients. Their importance is underscored by a growing focus on tissue engineering and regenerative medicine, which aims to improve graft survival rates and enhance recovery times.

Immunosuppressive Drugs are vital for transplant patients as they prevent organ rejection post-surgery, ensuring long-term success of transplants. The market for these medications has extended in response to rising patient needs, consequently leading to increased focus on personalized medicine approaches that tailor treatments to individual patient needs while minimizing potential side effects. Furthermore, Preservation Solutions are indispensable in the transplantation process, ensuring that organs remain viable for transplantation by safeguarding cell integrity during transportation.

The effectiveness of existing preservation methods has a direct impact on the success rates of transplant surgeries, hence seeing continued investment in research for innovative solutions. In the context of the US, the government has set several initiatives aimed at improving organ donation and transplantation processes, thereby further nurturing the market dynamics for these products. The US Transplantation Market demonstrates a robust path ahead, propelled by these critical segments, each holding significant importance in shaping treatment outcomes and improving the lives of patients undergoing organ transplants.

Together, they form an interconnected ecosystem that significantly impacts the overall success of transplantation efforts in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Transplantation Market Application Insights**

The Application segment of the US Transplantation Market highlights the growing demand for advanced medical procedures aimed at improving patient outcomes and extending life expectancy. Organ Transplantation plays a critical role in addressing the increasing incidence of organ failure, particularly among the aging population, where efforts to match donors and recipients are paramount due to the scarcity of available organs. Meanwhile, Tissue Transplantation has gained significance in restoring functionality and improving the quality of life for patients recovering from injuries and chronic diseases, thereby enhancing rehabilitation outcomes.

The US boasts a well-established regulatory framework and infrastructure supporting these transplantation procedures, which contributes to the steady growth of the market. Moreover, advancements in surgical technologies and immunosuppressive therapies are further bolstering the potential of both organ and tissue transplantation. As healthcare providers and organizations increasingly focus on improving transplant success rates and patient management, the Application segment is expected to thrive in tandem with rising healthcare expenditure and a greater emphasis on personalized medicine. This reflects a robust landscape for the US Transplantation Market, revealing numerous opportunities as healthcare dynamics evolve over the coming years.

### **Transplantation Market End User Insights**

The End User segment of the US Transplantation Market encompasses critical entities such as hospitals, transplantation centers, and other facilities that play pivotal roles in organ and tissue transplantation processes. Hospitals serve as primary healthcare providers, often housing specialized transplant units, which enables them to conduct a higher volume of transplant procedures. These institutions not only facilitate patient care but also participate in extensive research and collaboration to improve transplant outcomes and innovative techniques. Transplantation centers, dedicated to managing the full spectrum of transplantationfrom evaluation to post-operative careare crucial in ensuring patient success and quick recovery.

Their specialized focus allows for tailored treatment plans that align with the unique needs of candidates. Other facilities within this market, while smaller, also contribute significantly by supporting various stages of transplant care, including outpatient services and follow-up care necessary for ensuring long-term patient health. The robust demand for successful transplantation procedures and the rising prevalence of chronic diseases drive the growth within these segments, reflecting the need for advanced infrastructure and specialized medical personnel in the US Transplantation Market.

## **US Transplantation Market Key Players and Competitive Insights**

The competitive landscape of the US Transplantation Market is characterized by rapid advancements in medical technologies, coupled with a growing demand for organ transplants. This sector plays a crucial role in healthcare, addressing the challenges of organ shortages and improving patient outcomes through innovative solutions. Players in this market are focused on enhancing their product offerings, expanding their geographic reach, and fostering collaborations to leverage technological advancements. The increasing prevalence of chronic diseases, alongside a rising aging population, is propelling the need for transplantation, further intensifying competition among key market participants.

A strategic understanding of market dynamics, regulatory frameworks, and consumer needs is essential for companies seeking to establish or maintain a competitive edge in this vital healthcare sector.

Transplantation Technologies emerges as a prominent player within the US Transplantation Market by specializing in innovative solutions that facilitate organ transplantation. Their strengths lie in the development of cutting-edge preservation and transportation technologies, which are critical to ensuring the viability of transplanted organs. With a strong focus on research and development, Transplantation Technologies has positioned itself as a leader in overcoming logistical challenges related to organ preservation. Their portfolio includes advanced solutions that have significantly improved transplant success rates and minimized complications associated with organ damage during transit, thereby strengthening their market presence.

Additionally, their commitment to quality and patient safety further enhances their reputation and trust among healthcare professionals.

Genzyme has established itself as a key player in the US Transplantation Market through its diverse range of specialized products and services designed to improve transplant outcomes. Known for its innovative therapies, Genzyme has a robust portfolio that includes immunosuppressive drugs essential for preventing transplant rejection, thereby catering to the needs of both patients and healthcare providers. The company's strong market presence is further augmented by strategic partnerships and collaborations aimed at expanding their product offerings and enhancing research capabilities.

Genzyme's commitment to continuous improvement and innovation is reflected in its successful mergers and acquisitions, which have strengthened its position in the transplantation sector. Their ability to leverage these strengths and consistently adapt to evolving market demands places Genzyme in a favorable position to tackle the complexities and challenges of the US Transplantation Market.

### **Key Companies in the US Transplantation Market Include**

## **US Transplantation Market Industry Developments**

The US [Transplantation](../../../reports/transplantation-market-11866) Market has recently experienced significant developments with advancements in technologies and approaches to organ transplantation. In 2023, United Therapeutics expanded its portfolio focusing on developing transplantation solutions for lung and heart transplants, reflecting the rising demand for organ regeneration. Additionally, Bristol-Myers Squibb has been investing in Research and Development related to immunosuppressive therapies for transplant patients, consequently enhancing treatment options. Xenotransplantation continues to be a crucial area of research, with increasing support from industry players like Genzyme and Astellas Pharma as they explore animal-derived organs to address organ shortages.

In terms of mergers and acquisitions, in March 2023, Thermo Fisher Scientific announced the acquisition of HLA Technologies, which enhanced its product offerings within genetic matching for transplant candidates. Market valuation for companies in this sector remains strong, with consistent growth driven by innovation and an increasing focus on personalized medicine. Over the past two years, there has been a notable increase in collaboration among key players to improve clinical outcomes and expand access to transplant services across the United States, further underscoring the market's dynamic evolution.

## **US Transplantation Market Segmentation Insights**

### **Transplantation Market Product Type Outlook**

### **Transplantation Market Application Outlook**

### **Transplantation Market End User Outlook**

## Market Drivers

### Rising Incidence of Organ Failure

The increasing prevalence of chronic diseases such as diabetes and hypertension is contributing to a higher incidence of organ failure in the US. This trend is likely to drive demand within the transplantation market, as more patients require organ transplants to survive. According to recent statistics, approximately 120,000 individuals are currently on the waiting list for organ transplants, with kidney transplants being the most sought after. The growing patient population necessitates advancements in transplantation procedures and organ procurement strategies, thereby influencing the overall dynamics of the transplantation market. As the healthcare system adapts to these challenges, the market is expected to expand, potentially leading to increased investments in research and development of innovative transplant solutions.

### Advancements in Surgical Techniques

Innovations in surgical techniques and technologies are transforming the landscape of the transplantation market. Minimally invasive procedures, robotic-assisted surgeries, and enhanced imaging technologies are improving patient outcomes and reducing recovery times. For instance, laparoscopic techniques are becoming more prevalent in kidney transplants, which may lead to shorter hospital stays and lower complication rates. The adoption of these advanced surgical methods is likely to attract more patients seeking transplantation, thereby expanding the market. Additionally, the integration of artificial intelligence in surgical planning and execution could further enhance the precision and success rates of transplant surgeries, indicating a promising future for the transplantation market.

### Regulatory Support for Transplantation

The US government has been actively promoting policies that support organ donation and transplantation. Initiatives such as the Organ Procurement and Transplantation Network (OPTN) aim to streamline the organ allocation process and enhance the efficiency of transplantation services. This regulatory framework is likely to foster growth in the transplantation market by ensuring that more organs are available for transplantation. Furthermore, funding for research and development in transplantation technologies is being prioritized, which may lead to improved surgical techniques and post-operative care. As regulatory bodies continue to advocate for organ donation, the transplantation market could experience a surge in activity, benefiting both patients and healthcare providers.

### Increased Collaboration Among Healthcare Providers

Collaboration among healthcare providers, including hospitals, transplant centers, and research institutions, is becoming increasingly vital in the transplantation market. Such partnerships facilitate knowledge sharing, resource allocation, and the development of best practices in organ transplantation. By working together, these entities can improve patient care and streamline the transplantation process, ultimately leading to better outcomes. The establishment of networks that connect various stakeholders in the transplantation ecosystem may enhance organ donation rates and optimize the use of available organs. This collaborative approach is expected to drive growth in the transplantation market, as it fosters innovation and efficiency in addressing the challenges faced by patients in need of transplants.

### Growing Investment in Biologics and Regenerative Medicine

The transplantation market is witnessing a surge in investment directed towards biologics and regenerative medicine. These fields focus on developing therapies that can enhance organ function and promote healing, potentially reducing the need for transplants. For example, stem cell therapies are being explored as a means to regenerate damaged tissues and organs, which could alleviate some of the pressures on the transplantation market. As research progresses, the commercialization of these innovative therapies may provide alternative solutions for patients with organ failure, thereby reshaping the market landscape. The financial backing from both public and private sectors is likely to accelerate advancements in this area, fostering a more robust transplantation market.

## Future Outlook

The [Transplantation Market](https://www.marketresearchfuture.com/reports/transplantation-market-11866) is projected to grow at a 9.5% CAGR from 2025 to 2035, driven by technological advancements, increasing organ demand, and enhanced regulatory frameworks.

**New opportunities:**

- Development of advanced organ preservation technologies for improved transplant viability.
- 
- Expansion of telehealth services for pre- and post-transplant patient management.
- Investment in AI-driven matching algorithms to optimize donor-recipient pairing.

By 2035, the transplantation market is expected to achieve substantial growth, driven by innovation and increased accessibility.

## Segment Insights

### By Organ Type: Kidney (Largest) vs. Liver (Fastest-Growing)

In the US [transplantation market](https://www.marketresearchfuture.com/reports/transplantation-market-11866), the distribution of organ types reveals that kidneys account for the largest share due to their crucial role in treating chronic kidney disease. The liver follows as a vital organ, reflecting a steady market presence. Heart and lung transplants, while significant, have relatively smaller market shares. Pancreas transplants remain less common but are essential for specific diabetes treatments. Growth trends in this segment highlight the increasing demand for kidney and liver transplants, driven by rising incidences of chronic diseases and advancements in surgical techniques. The liver segment is emerging as the fastest-growing due to increased awareness about liver health and successful transplant outcomes. Innovations in organ preservation techniques and donor matching protocols also contribute to this growth.

Kidney (Dominant) vs. Liver (Emerging)

Kidney transplants continue to dominate the organ transplantation segment, reflecting robust distribution and a well-established network of donor and transplant centers. Their effectiveness in treating end-stage renal disease solidifies their position. In contrast, the liver segment, while still significant, is labeled as emerging due to the rising incidence of liver diseases and the growing number of successful transplant operations. Initiatives to enhance public awareness about organ donation are expected to propel the liver segment forward. The dynamic nature of liver transplantation, coupled with improved medical practices, positions it as a compelling area of growth within the market.

### By Transplantation Type: Deceased Donor Transplantation (Largest) vs. Living Donor Transplantation (Fastest-Growing)

In the US transplantation market, the deceased donor transplantation segment dominates, accounting for a significant share of the total procedures. This segment benefits from a larger donor pool, facilitated by ongoing awareness campaigns and policy improvements. Conversely, living donor transplantation is growing rapidly, driven by advancements in surgical techniques and increased public awareness regarding the benefits of living donations. Growth trends reflect a positive shift towards innovative practices in transplantation, especially with the introduction of regulations that encourage living donations. This change is propelled by technological advancements in immunosuppression and transplant matching, which improve outcomes and minimize complications. Additionally, xenotransplantation is emerging, driven by research into gene editing and animal organ use, further diversifying the transplantation landscape.

Deceased Donor Transplantation (Dominant) vs. Living Donor Transplantation (Emerging)

Deceased donor transplantation remains the dominant force in the US transplantation market, characterized by a complex network that includes hospitals, organ procurement organizations, and logistics for donor organ recovery and allocation. Its stability is rooted in established processes and vast clinical experience. On the other hand, living donor transplantation is positioned as an emerging segment that capitalizes on the growing acceptance and encouragement of living organ donations. This segment is gathering momentum due to its ability to reduce wait times and improve outcomes for recipients. The integration of educational programs and support networks for donors and facilities reflects the commitment to expand this avenue, inviting more individuals to consider becoming living donors.

### By Application: Solid Organ Transplantation (Largest) vs. Stem Cell Transplantation (Fastest-Growing)

In the US transplantation market, Solid Organ Transplantation dominates the market share, driven by high demand for kidney, liver, and heart transplants that have well-established protocols and infrastructure. On the other hand, Stem Cell Transplantation, while smaller in market share, is gaining significant traction owing to advancements in regenerative medicine and increased awareness of its therapeutic potential for various conditions such as leukemia and other blood disorders. The growth trends in the US transplantation market are characterized by an increasing number of transplant procedures, supported by improvements in surgical techniques and post-operative care. Furthermore, collaborative efforts between healthcare providers, research institutions, and regulatory bodies are propelling innovation in transplantation methods. As technological innovations evolve, Stem Cell Transplantation is poised to become a key player, thus making it the fastest-growing segment in the market fueled by expanding clinical applications and favorable regulatory environments.

Solid Organ Transplantation (Dominant) vs. Stem Cell Transplantation (Emerging)

Solid Organ Transplantation plays a pivotal role in fulfilling the needs of patients suffering from organ failure. It encompasses a range of procedures that involve the transplantation of vital organs, with strong support from transplant networks and dedicated healthcare teams. The segment is characterized by its robustness, extensive surgical experience, and significant ongoing research to improve outcomes and reduce rejection rates. Meanwhile, Stem Cell Transplantation, an emerging segment, is rapidly evolving with innovative techniques such as CAR-T cell therapy offering new hope for patients with malignancies and genetic disorders. This segment benefits from a dynamic landscape of clinical research and technology development, positioning it as a promising frontier in regenerative health solutions.

### By End-use: Hospitals (Largest) vs. Transplant Centers (Fastest-Growing)

In the US transplantation market, Hospitals dominate the end-use segment, capturing a significant share of the market due to their broad capabilities in surgical procedures and patient management. Transplant Centers also hold a substantial position, focusing on specialized care and post-operative support, which allows them to cater effectively to their patient demographics. Specialty Clinics, while important, play a smaller role in comparison and primarily serve niche markets that complement the offerings of Hospitals and Transplant Centers. Growth trends in the end-use segment indicate that Transplant Centers are emerging as the fastest-growing segment, driven by advancements in transplant technology and an increase in organ donor availability. Meanwhile, Hospitals continue to evolve, enhancing their transplant protocols and incorporating innovative care models, which support their dominant position. As awareness and demand for organ transplants rise, both segments are likely to benefit from improved healthcare policies and an increased focus on specialized care.

Hospitals (Dominant) vs. Transplant Centers (Emerging)

Hospitals serve as the dominant players in the end-use segment, benefiting from their established infrastructure and comprehensive medical services. They have the necessary resources for complex transplant surgeries and post-operative care, enabling them to handle a large volume of procedures. Their integration with various departments facilitates seamless patient care across the entire transplant process. In contrast, Transplant Centers are emerging as pivotal entities focused on specialized transplantation services. They provide tailored care and support, ensuring higher success rates and patient satisfaction. Their ability to adapt to new transplant innovations and patient demands positions them well in the evolving landscape of the US transplantation market.

## Competitive Benchmarking

The transplantation market exhibits a dynamic competitive landscape characterized by rapid advancements in technology and a growing emphasis on patient-centric solutions. Key players such as AbbVie (US), Thermo Fisher Scientific (US), and Medtronic (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. AbbVie (US) focuses on expanding its immunosuppressive drug portfolio, while Thermo Fisher Scientific (US) emphasizes the development of advanced diagnostic tools that facilitate organ compatibility assessments. Medtronic (US) is actively pursuing digital health solutions to improve post-transplant patient monitoring, thereby enhancing overall outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient care.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The transplantation market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements. This competitive structure fosters an environment where smaller firms can innovate, yet larger entities dominate through established networks and resources.
In October AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunosuppressive agent aimed at reducing organ rejection rates. This collaboration is significant as it not only enhances AbbVie’s product pipeline but also positions the company to address unmet needs in transplant medicine, potentially leading to improved patient outcomes and market share.
In September Thermo Fisher Scientific (US) launched a new line of genomic analysis tools designed to streamline organ compatibility testing. This initiative is crucial as it reflects the growing trend towards personalized medicine in transplantation, allowing for more precise matching of donors and recipients, which could significantly reduce transplant rejection rates.
In August Medtronic (US) unveiled a digital health platform that integrates real-time monitoring of transplant patients, enabling healthcare providers to track vital signs and medication adherence remotely. This move is indicative of the increasing integration of technology in healthcare, particularly in transplantation, where timely interventions can be critical to patient survival and recovery.
As of November the transplantation market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into clinical practices. Strategic alliances are becoming increasingly important, as they enable companies to pool resources and expertise to tackle complex challenges in transplantation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the necessity for companies to adapt and innovate continuously to maintain a competitive edge in a rapidly changing landscape.

## Recent News & Developments

The US [Transplantation](../../../reports/transplantation-market-11866) Market has recently experienced significant developments with advancements in technologies and approaches to organ transplantation. In 2023, United Therapeutics expanded its portfolio focusing on developing transplantation solutions for lung and heart transplants, reflecting the rising demand for organ regeneration. Additionally, Bristol-Myers Squibb has been investing in Research and Development related to immunosuppressive therapies for transplant patients, consequently enhancing treatment options. Xenotransplantation continues to be a crucial area of research, with increasing support from industry players like Genzyme and Astellas Pharma as they explore animal-derived organs to address organ shortages.

In terms of mergers and acquisitions, in March 2023, Thermo Fisher Scientific announced the acquisition of HLA Technologies, which enhanced its product offerings within genetic matching for transplant candidates. Market valuation for companies in this sector remains strong, with consistent growth driven by innovation and an increasing focus on personalized medicine. Over the past two years, there has been a notable increase in collaboration among key players to improve clinical outcomes and expand access to transplant services across the United States, further underscoring the market's dynamic evolution.

## Report Scope

| MARKET SIZE 2024 | 4131.43(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4523.92(USD Million) |
| MARKET SIZE 2035 | 11213.9(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie (US), Thermo Fisher Scientific (US), Medtronic (US), Fresenius Medical Care (DE), Astellas Pharma (JP), Novartis (CH), Bristol-Myers Squibb (US), Sandoz (CH), Organogenesis (US) |
| Segments Covered | Organ Type, Transplantation Type, Application, End-use |
| Key Market Opportunities | Advancements in organ preservation technologies enhance transplant success rates and expand donor organ viability. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth and competition in the transplantation market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US transplantation market in 2024?**
A: The overall market valuation was $4131.43 Million in 2024.

**Q: What is the projected market valuation for the US transplantation market by 2035?**
A: The projected valuation for 2035 is $11213.9 Million.

**Q: What is the expected CAGR for the US transplantation market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 9.5%.

**Q: Which organ type had the highest market valuation in 2024?**
A: In 2024, the kidney segment had the highest market valuation at $1500 Million.

**Q: What are the market valuations for deceased donor and living donor transplantation in 2024?**
A: In 2024, deceased donor transplantation was valued at $2000 Million, while living donor transplantation was valued at $1800 Million.

**Q: What is the market valuation for solid organ transplantation in 2024?**
A: The market valuation for solid organ transplantation in 2024 was $1500 Million.

**Q: Which end-use segment had the highest valuation in 2024?**
A: In 2024, hospitals had the highest valuation among end-use segments at $1650 Million.

**Q: What is the market valuation for pancreas transplantation in 2024?**
A: The market valuation for pancreas transplantation in 2024 was $131.43 Million.

**Q: Which key players are leading the US transplantation market?**
A: Key players in the market include AbbVie, Thermo Fisher Scientific, Medtronic, and Bristol-Myers Squibb.

**Q: What is the projected growth trend for tissue transplantation from 2025 to 2035?**
A: Tissue transplantation is expected to grow significantly, with a valuation projected to reach $4213.9 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-transplantation-market-15860*